Theon International (THEON) investor relations material

Executive summary

• Achieved 32.3% year-over-year revenue growth in Q1 2026, reaching €120.1 million, with platform products contributing 7% of total revenue.

• Organic and inorganic growth strategies advanced, including major acquisitions: 9.8% of Exosens S.A. (€268.7M), 100% of Kappa Optronics GmbH (€69.9M), and a 30% stake in Al Meezan Limited post-period.

• Entered strategic partnerships and secured significant new orders, including €41M for night vision and thermal devices, and a €40M+ contract with Rheinmetall Electronics.

• Platform-based products and geographic diversification are contributing to top-line expansion.

• Q1 2026 delivered strong revenue growth and margin resilience, with continued confidence in full-year guidance and medium-term targets.

Financial highlights

• Adjusted EBITDA rose 29% year-over-year to €31.8M; Adjusted EBIT up 26% to €30.0M, with a 25% margin.

• EPS increased to €0.692 from €0.25, driven by financial asset performance, notably Exosens.

• Net assets at €253.9M (up from €236.2M at year-end); total assets €437.7M.

• Net debt position shifted to €228.2M from net cash of €126.9M at year-end, reflecting acquisition activity; leverage (Net Debt/LTM EBITDA) at 1.8x.

• Order intake declined 40.6% to €70M due to seasonality, but options added €40M to future potential; soft backlog stable at €1,420M.

Outlook and guidance

• FY 2026 revenue guidance reaffirmed at €570–600M, with mid-twenties adjusted EBIT margin.

• Organic growth target above 15% per annum, supported by bolt-on M&A.

• Capex expected at €30M; dividend proposal of €24.4M at upcoming AGM.

• Platform products targeted to represent 20% of group revenues in the medium term.

• Committed to reducing NWC absorption to below 35% medium-term.